Supplement for Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://data.mendeley.com/datasets/s4jfrybx29
下载链接
链接失效反馈官方服务：
资源简介：
Supplemental material for the Bissonnette et al. Tapinarof Cream ADORING 3 Phase 3 Long-term Trial in AD article
创建时间：
2025-05-06
